Gender affirming hormones prescribed
| Transwomen (n=46) | Transmen (n=29) | |
| Gender affirming hormones prescribed | Oral oestradiol: 67.4% Transdermal oestradiol: 15.2% Oestradiol valerate IM: 13.0% Oestradiol cypionate IM: 2.2% Unknown: 2.2% | Testosterone cypionate: 89.7% Testosterone enanthate: 3.4% Transdermal testosterone: 3.4% Testosterone 2% gel: 3.4% |
| Time to first therapeutic level (39 transwomen, 26 transmen) (days) (median (range)) | 234.0 (27–1270) | 98.5 (23–1116) |
| Testosterone blockade prescribed (transwomen only) | Spironolactone: 80.4% Spironolactone and finasteride: 13.0% GnRH agonist IM: 2.2% GnRH agonist and spironolactone: 2.2% Unknown: 2.2% | |
| Time to first documented suppression (n=35) (days) (median (range)) | 200 (27–979) | |
GnRH, gonadotropin releasing hormone.